Qi Li, Liu Qin, Qi Xiaoling, Wu Na, Tang Wenge, Xiong Hongyan
Department of Military Epidemiology, College of Military Prevention, Third Military Medical University, Chongqing, China.
Chongqing Municipal Center for Disease Control and Prevention, Chongqing, China.
BMC Public Health. 2015 May 6;15:471. doi: 10.1186/s12889-015-1798-y.
To assess the effects of peer support at improving glycemic control in patients with type 2 diabetes.
Relevant electronic databases were sought for this investigation up to Dec 2014. Randomized controlled trials involving patients with type 2 diabetes that evaluated the effect of peer support on glycated hemoglobin (HbA1c) concentrations were included. The pooled mean differences (MD) between intervention and control groups with 95% confidence interval (CI) were calculated using random-effects model. The Cochrane Collaboration's tool was used to assess the risk of bias.
Thirteen randomized controlled trials met the inclusion criteria. Peer support resulted in a significant reduction in HbA1c (MD -0.57 [95% CI: -0.78 to -0.36]). Programs with moderate or high frequency of contact showed a significant reduction in HbA1c levels (MD -0.52 [95% CI: -0.60 to -0.44] and -0.75 [95% CI: -1.21 to -0.29], respectively), whereas programs with low frequency of contact showed no significant reduction (MD -0.32 [95% CI: -0.74 to 0.09]). The reduction in HbA1c were greater among patients with a baseline HbA1c ≥ 8.5% (MD -0.78 [95% CI: -1.06 to -0.51]) and between 7.5 ~ 8.5% (MD -0.76 [95% CI: -1.05 to -0.47]), than patients with HbA1c < 7.5% (MD -0.08 [95% CI: -0.32 to 0.16]).
Peer support had a significant impact on HbA1c levels among patients with type 2 diabetes. Priority should be given to programs with moderate or high frequency of contact for target patients with poor glycemic control rather than programs with low frequency of contact that target the overall population of patients.
评估同伴支持对改善2型糖尿病患者血糖控制的效果。
截至2014年12月,检索相关电子数据库进行此项调查。纳入涉及2型糖尿病患者且评估同伴支持对糖化血红蛋白(HbA1c)浓度影响的随机对照试验。采用随机效应模型计算干预组与对照组之间的合并平均差值(MD)及95%置信区间(CI)。使用Cochrane协作网的工具评估偏倚风险。
13项随机对照试验符合纳入标准。同伴支持使HbA1c显著降低(MD -0.57 [95% CI:-0.78至-0.36])。接触频率为中等或高的项目使HbA1c水平显著降低(MD分别为-0.52 [95% CI:-0.60至-0.44]和-0.75 [95% CI:-1.21至-0.29]),而接触频率低的项目未显示出显著降低(MD -0.32 [95% CI:-0.74至0.09])。基线HbA1c≥8.5%的患者(MD -0.78 [95% CI:-1.06至-0.51])和HbA1c在7.5%至8.5%之间的患者(MD -0.76 [95% CI:-1.05至-0.47])的HbA1c降低幅度大于HbA1c<7.5%的患者(MD -0.08 [95% CI:-0.32至0.16])。
同伴支持对2型糖尿病患者的HbA1c水平有显著影响。对于血糖控制不佳的目标患者,应优先选择接触频率为中等或高的项目,而非针对全体患者的接触频率低的项目。